Petros Pharmaceuticals, Inc.
PTPI
$0.032
$0.00082.56%
OTC PK
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -20.67% | -12.20% | -42.41% | 6.96% | -22.36% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -20.67% | -12.20% | -42.41% | 6.96% | -22.36% |
| Cost of Revenue | -18.47% | -46.00% | -67.12% | -59.88% | -54.36% |
| Gross Profit | 27.81% | -32.18% | -59.84% | 13.35% | -39.52% |
| SG&A Expenses | -13.18% | -18.58% | -3.61% | -8.49% | -17.32% |
| Depreciation & Amortization | -13.96% | -35.63% | -33.47% | -43.18% | -49.51% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -19.01% | -30.09% | -17.93% | -24.71% | -26.22% |
| Operating Income | 28.57% | 26.87% | -13.61% | 23.51% | 17.52% |
| Income Before Tax | -108.84% | -44.22% | 82.84% | 79.48% | 69.90% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -108.84% | -44.22% | 82.83% | 79.48% | 69.90% |
| Earnings from Discontinued Operations | 58.34% | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -61.24% | -75.41% | 62.79% | 67.90% | 57.92% |
| EBIT | 28.57% | 26.87% | -13.61% | 23.51% | 17.52% |
| EBITDA | 35.69% | 32.62% | -27.32% | 22.56% | 7.57% |
| EPS Basic | 68.10% | 42.21% | 37.69% | 38.38% | 28.30% |
| Normalized Basic EPS | 68.71% | 77.85% | 98.33% | 71.03% | 52.88% |
| EPS Diluted | 68.10% | 42.21% | 37.69% | 38.38% | 28.30% |
| Normalized Diluted EPS | 68.71% | 77.85% | 98.33% | 71.03% | 52.88% |
| Average Basic Shares Outstanding | 395.67% | 268.66% | 189.91% | 99.37% | 37.06% |
| Average Diluted Shares Outstanding | 395.67% | 268.66% | 189.91% | 99.37% | 37.06% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |